HealthQuill National Cancer Institute
Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the French company will invest 300 million euros for a 16% equity.
Drugs Health Pharma

Sanofi to invest $324m in entity with Orano Med for radioligand therapy

Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the.

Read More
https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_ppi.pdf
Drugs Health Pharma

Merck meets main goal during end-stage trial of HPV vaccine in Japan

Merck & Co., announced it has met its primary and secondary goals during the end-stage trials of its human papillomavirus (HPV) vaccine in.

Read More
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment of Merck & Co.
Drugs Health Pharma

Roche ends small cell lung cancer trials as results show ‘reduced efficacy’

Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.

Read More
https://www.cancer.gov/news-events/press-releases/2024/genetic-factors-predict-x-chromosome-loss
Drugs Health Pharma

Genetic factors may help predict loss of X chromosome in older women

Researchers co-led by the US-based National Cancer Institute have found genetic variants in women that may play a role in promoting abnormal blood.

Read More